BERLIN, March 15, 2007 - The Berlin-based biotechnology company MOLOGEN AG announced today that they have successfully completed a capital increase. A total of 800.000 shares were placed with institutional investors without subscription rights. The company’s subscribed capital has increased by 9.4 percent to Euro 9.29 million. The issue price is above the average share price of the last trading days and furthermore the capital increase was oversubscribed. The issue grossed about Euro 6 million.
